I have no qualms with those who believe it is the responsibility of the
management of public companies to communicate clearly and accurately
with investors (and analysts) about the current state of the business
and the likely near-term conditions. Likewise, I don't particularly
object when the Street punishes those companies that come in short of
expectations without having given suitable warning.
So I can understand some of the disappointment with Hologic (Nasdaq:HOLX)
these days – the company arguably could have done a better job
communicating (and adjusting expectations) in regards to the fall-off in
2D mammography, ThinPrep, and the Chinese business. At the same time,
though, I see a lot of what's troubling Hologic as macro issues
impacting the sector as a whole. As the company is continuing to execute
reasonably well on costs and the Gen-Probe integration, today's share
price may be something of an opportunity.
Please continue here:
http://www.investopedia.com/stock-analysis/050813/recent-financials-may-not-be-entirely-fair-hologic-holx-bdx-qgen-ge-jnj-phg.aspx
No comments:
Post a Comment